Idogen AB has received confirmation that the European Patent Office (EPO) intends to grant a patent application which supports and covers the company's tolerogenic cell therapy's application to the severe bleeding disorder, hemophilia A. This patent application was submitted in 2016 and will provide additional protection to the broader patent application for Idogen's technology which in December 2020 was extended via an International (PCT) application.
-This is very positive news from the European Patent Office (EPO). The patent covers Idogen's technology to inhibit the production of neutralizing antibodies against treatment with blood factors such as Factor VIII (FVIII) by inducing immune tolerance. This patent will provide additional protection and strengthen the company's patent portfolio for IDO 8, for which we intend to initiate clinical studies during the second half of 2021, says Anders Karlsson CEO at Idogen.
When the patent (Patent Application No. EP16710978.4) is granted, it will protect this technical space until 2036. The final grant of this patent by the EPO is expected to occur within two to three months following the completion of routine formalities by Idogen. A similar application is pending in the US.The granted patent will provide important complementary protection to that sought via the International (PCT) application for Idogen's new, innovative method for cell therapy that was filed in December 2020. That patent application will, following grant, provide the company with a patent protection and market exclusivity until 2040.
For further information, please contact:
Anders Karlsson, CEO Idogen AB
Phone: +46 (0) 709 18 00 10
This information was submitted for publication, through the agency of the contact person set out above, at 11:10 CET on February 25, 2021.
The company's Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm; tel: +46 (0) 8-463 80 00, email:
Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissues. The company's most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralising antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favourable safety profile and long-lasting effect. The potential for a short-term treatment to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.